United States Drug Manufacturers - General news

02:19 22 Jul 2026

European AIDS Treatment Group Regulatory and legal Main company 🇺🇸 United States

[AIDS 2026] [Press release] Gilead & Merck: Investigational once-weekly oral HIV treatment regimen of islatravir and lenacapavir maintained virological suppression in adults with HIV who switched antiretroviral therapy

Gilead Sciences and Merck will present detailed outcomes from their Phase 3 ISLEND-1 and ISLEND-2 trials at AIDS 2026. The investigational once-weekly oral HIV treatment regimen of islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) demonstrated effectiveness in virally suppressed adults with HIV who switched from …

MRK main company GILD main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

02:10 22 Jul 2026

Market source Earnings Main company 🇺🇸 United States

How Investors May Respond To AbbVie (ABBV) Securing EU Approval For Short-Acting Boey Aesthetic Toxin

AbbVie (ABBV) recently secured EU approval for Boey, a short-acting aesthetic toxin for treating glabellar lines, which broadens its aesthetics portfolio. While this approval adds incremental support, the primary drivers for AbbVie's investment narrative remain its immunology and neuroscience engines, balancing patent losses and …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

02:08 22 Jul 2026

Investing.com Deals and strategy Main company 🇺🇸 United States

Johnson & Johnson EVP Broadhurst sells $5.79m in stock

Vanessa Broadhurst, EVP of Global Corporate Affairs at Johnson & Johnson, sold 23,054 shares of company stock for approximately $5.79 million. Simultaneously, she acquired the same number of shares through the exercise of employee stock options totaling $3.01 million. These transactions have resulted in …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

00:11 22 Jul 2026

Moomoo Earnings Main company 🇺🇸 United States

Novartis AG 2Q Net Pft $3.3B

Novartis AG announced its second-quarter net profit of $3.3 billion. This figure indicates the company's financial performance during that period.

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

00:08 22 Jul 2026

BBC Regulatory and legal Main company 🇺🇸 United States

Ozempic-maker Novo Nordisk accuses rival Eli Lilly of false advertising

Novo Nordisk, the maker of Ozempic and Wegovy, has filed a lawsuit against rival Eli Lilly, accusing it of false advertising. Novo Nordisk claims Eli Lilly's ad campaigns for Mounjaro and Zepbound misleadingly present their drugs as superior by comparing their highest doses to …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

00:06 22 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

EBIT per share of AbbVie, Inc. – BCS:ABBVCL1

This article provides financial information for AbbVie, Inc. under the ticker ABBVCL1 on the Santiago Stock Exchange, specifically focusing on its EBIT per share. It indicates that the market is currently closed with no trades. The content is primarily a data page from TradingView, …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

23:15 21 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Novo Nordisk (CPSE:NOVO B) Stock Looks Reasonable On Earnings While Returns Stay Weak

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk stock has had a tough stretch over the past few years, yet current valuation checks suggest the market may now be pricing it …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

23:06 21 Jul 2026

Yahoo! Finance Canada Earnings Main company 🇺🇸 United States

AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know

AbbVie (ABBV) stock closed up 1.11% in its latest trading session, outperforming the S&P 500 and the Medical sector over the past month. The company is set to release its Q2 earnings on July 31, 2026, with analysts predicting significant growth in EPS and …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

22:13 21 Jul 2026

Yahoo! Finance Canada Earnings Main company 🇺🇸 United States

Bristol Myers Squibb (BMY) Opens 427,000 Square Foot San Diego Hub For AI Drug Discovery

Bristol Myers Squibb (BMY) has opened a significant 427,000 square foot R&D hub in San Diego, integrating NVIDIA-powered AI infrastructure to accelerate drug discovery. This initiative aims to enhance the speed and efficiency of its oncology, cardiovascular, and immunology programs, potentially offsetting patent expiries …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

21:38 21 Jul 2026

Moomoo Earnings Main company 🇺🇸 United States

Press Release: Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Gilead Sciences announced its plans to release second-quarter 2026 financial results on Tuesday, August 4, 2026. The company will host a webcast and conference call to discuss these results later that day. Interested parties can access the webcast and accompanying slides on the company's …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

21:37 21 Jul 2026

TradingView Market update Main company 🇺🇸 United States

ETFs Investing in Gilead Sciences, Inc. Stocks

This article lists various ETFs that include Gilead Sciences, Inc. (GILD0) stocks in their portfolios. The ETFs are sorted by market value and provide details such as weight, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, and 3-year NAV total …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

21:08 21 Jul 2026

TradingView Market update Main company 🇺🇸 United States

Non-controlling/minority interest of Merck & Co., Inc. – BCS:MRKCL1

This page provides financial information for Merck & Co., Inc. (MRKCL1) traded on the Santiago Stock Exchange, specifically focusing on its non-controlling/minority interest. It notes that the market is currently closed with no trades. The content primarily displays navigation and boilerplate information without specific …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

21:05 21 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Top Research Reports for Eli Lilly, Costco & Morgan Stanley

Tuesday, July 21, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Costco Wholesale Corp. (COST) and Morgan Stanley (MS), as well …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

21:02 21 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

AI is helping speed up the timelines of drug discovery, Novartis CEO says

Novartis stock (NVS) gets a lift higher on Tuesday after topping second quarter earnings estimates. Novartis CEO Vas Narasimhan sits down with Julie Hyman to talk more about the pharma giant's research into utilizing AI to aid in new drug discovery. Video Transcript 00:00 …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

20:33 21 Jul 2026

Bloomberg Law News Market update Main company 🇺🇸 United States

Amgen Settles Investor Suit Over Tax Liability for $74 Million

Amgen Inc. has agreed to a $74 million settlement in an investor lawsuit. The suit alleged that the pharmaceutical company delayed informing investors about potential tax liabilities totaling $10.7 billion with the IRS. The proposed settlement covers investors who purchased Amgen stock between July …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

20:06 21 Jul 2026

TradingView Market update Main company 🇺🇸 United States

Enterprise value of AbbVie, Inc. – BCS:ABBV0

This article from TradingView is a placeholder page for the enterprise value of AbbVie, Inc. (BCS:ABBV0) on the Santiago Stock Exchange. It provides market data, financial links, and community features, but lacks specific valuation data. The page indicates that the market is closed and …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

20:06 21 Jul 2026

Trefis Earnings Main company 🇺🇸 United States

AbbVie Stock Zigs When The Market Zags

AbbVie (ABBV) stock has shown a counter-cyclical pattern, rising even as the broader market declines, with a low correlation to the S&P 500. This is attributed to its strong business fundamentals, including growth in immunology drugs like Skyrizi and Rinvoq, and recent positive Phase …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

19:56 21 Jul 2026

finance.yahoo.com Market update Main company 🇺🇸 United States

Novo sues Lilly, claiming misleading ads in weight-loss drug battle

View Comments

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

19:51 21 Jul 2026

Scripps News Regulatory and legal Main company 🇺🇸 United States

Novo Nordisk sues Eli Lilly, alleging the company's GLP-1 ads are 'deliberately false'

Novo Nordisk has filed a lawsuit against Eli Lilly, claiming that the latter's GLP-1 weight-loss drug ads for Zepbound are "deliberately false." Novo Nordisk alleges that Eli Lilly's advertisements for Zepbound deceptively suggest superior weight loss compared to Novo Nordisk's Wegovy, based on outdated …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

19:50 21 Jul 2026

grafa.com Regulatory and legal Main company 🇺🇸 United States

Gilead and Merck report weekly HIV trial results

Gilead Sciences (NASDAQ:GILD) and Merck (NYSE:MRK) have announced successful 48-week results for their once-weekly oral HIV regimen in two Phase 3 trials, ISLEND-1 and ISLEND-2. The trials showed that the treatment maintained viral suppression with a low percentage of patients above the viral-load threshold, …

MRK main company GILD main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

19:41 21 Jul 2026

Simply Wall Street Earnings Main company 🇺🇸 United States

Johnson & Johnson (JNJ) Stock Looks Fairly Valued With Cash Flow Upside

Johnson & Johnson (JNJ) stock shows a mixed valuation picture, with a discounted cash flow (DCF) model suggesting it is 34.1% undervalued, while its P/E ratio indicates fair valuation close to its modeled fair P/E and slightly above industry average. The company's future growth …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

19:37 21 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Total liabilities & shareholders' equities of Biogen Inc. – BCS:BIIB1

The article provides financial information for Biogen Inc. (BCS:BIIB1) on the Santiago Stock Exchange, specifically focusing on its total liabilities and shareholders' equities. It appears to be a financial data page from TradingView, offering an overview of the company's financial metrics. The page is …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

18:38 21 Jul 2026

TradingView Balance sheet Main company 🇺🇸 United States

Debt to equity ratio of Gilead Sciences, Inc. – BCS:GILD0

This article focuses on the debt to equity ratio of Gilead Sciences, Inc. (BCS:GILD0). While the information primarily consists of navigation and boilerplate text from a financial platform, it highlights the availability of financial data for the company on the Santiago Stock Exchange via …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

18:30 21 Jul 2026

WashU Medicine Deals and strategy Main company 🇺🇸 United States

WashU announces new academic-industry collaboration with Bristol Myers Squibb

Washington University in St. Louis and Bristol Myers Squibb have initiated a multiyear collaboration to foster scientific exchange and advance drug development in neuroscience. This partnership will provide WashU medical and research trainees with opportunities to work alongside Bristol Myers Squibb scientists and will …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

18:28 21 Jul 2026

Benzinga Market update Main company 🇺🇸 United States

Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill

Gilead Sciences and Merck & Co. have announced positive Phase 3 trial results for their investigational once-weekly oral HIV regimen, ISL/LEN. The treatment demonstrated non-inferior efficacy to daily antiretroviral therapy and showed high patient satisfaction due to reduced treatment burden. These findings are expected …

MRK main company GILD main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

18:12 21 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Novartis Profit Beats Estimates as Entresto Sales Plunge 50%

This article first appeared on GuruFocus. Novartis AG (NYSE:NVS), a Swiss pharmaceutical company focused on innovative medicines, reported stronger-than-expected second-quarter results as newer cancer treatments helped offset declining sales from its former blockbuster heart drug Entresto. Earnings excluding certain items remained unchanged at $5.94 …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

18:10 21 Jul 2026

Market source Earnings Main company 🇺🇸 United States

By mid-2027, analysts expect £6,000 in GSK shares to be worth…

Analysts predict that a £6,000 investment in GSK (LSE: GSK) shares could grow to over £6,700 within 12 months, and nearly £6,900 with dividends. Despite recent stagnation and some setbacks like the halt of a key drug development, the company's low valuation and the …

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

18:10 21 Jul 2026

Fierce Pharma Deals and strategy Main company 🇺🇸 United States

Sanofi continues tweaks to executive roster as new CEO Garijo settles in

Sanofi is continuing to adjust its executive team under new CEO Belén Garijo, with several notable changes including expanding the role of vaccine chief Thomas Triomphe to include China, and Madeleine Roach becoming president for Germany, Switzerland, and Austria. The company also announced the …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

18:08 21 Jul 2026

TradingView Market update Main company 🇺🇸 United States

Preferred dividends of Gilead Sciences, Inc. – BCS:GILDCL1

This page provides information on the preferred dividends of Gilead Sciences, Inc. under the ticker BCS:GILDCL1 on the Santiago Stock Exchange. It indicates that the market was closed with no trades recorded regarding these dividends.

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

17:16 21 Jul 2026

finance.yahoo.com Analyst action Main company 🇺🇸 United States

Update: Novo Nordisk Sues Eli Lilly Over Zepbound, Mounjaro Advertising

(Updates with Eli Lilly's response in the fifth and sixth paragraphs.) Novo Nordisk (NVO) said Tu PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

17:15 21 Jul 2026

TradingKey Earnings Main company 🇺🇸 United States

Novartis AG Stock (NVS) Moved Up by 3.42% on Jul 21: Key Drivers Unveiled

Novartis AG (NVS) stock increased by 3.42% on July 21st, driven by a strong quarterly earnings report that surpassed analyst expectations and an upgraded full-year guidance. The company's performance was bolstered by growth in its oncology and immunology segments, successful cost-saving synergies from restructuring, …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

17:13 21 Jul 2026

Amgen Market update Main company 🇺🇸 United States

More Than Dry Eyes: The Many Faces of Sjögren’s Disease

This article highlights the diverse manifestations of Sjögren's disease through the experiences of three women—Elaine, Courtney, and Rose—demonstrating that the autoimmune condition extends far beyond typical dry eyes and mouth. It explores the varied paths to diagnosis, the evolving and often debilitating symptoms like …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

17:08 21 Jul 2026

Sharecast.com Regulatory and legal Main company 🇺🇸 United States

Novo Nordisk files lawsuit against Eli Lilly for 'misleading' weight-loss drug ads

Novo Nordisk has filed a lawsuit against Eli Lilly & Co in the US District Court in New Jersey, accusing the rival pharmaceutical company of using "misleading" and "deceptive" advertising for its weight-loss drugs. The suit alleges violations of federal and state false advertising …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

17:07 21 Jul 2026

TradingView Market update Main company 🇺🇸 United States

Discontinued operations of Biogen Inc. – BCS:BIIB0

This article from TradingView indicates that Biogen Inc.'s operations, specifically under the ticker BCS:BIIB0 on the Santiago Stock Exchange, have been discontinued. The page displays "No trades" and is focused on financial data and stock information for the company.

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

16:53 21 Jul 2026

Fierce Pharma Regulatory and legal Main company 🇺🇸 United States

Amgen agrees to $74M settlement to resolve investor lawsuit over potential $10.7B tax bill

Amgen has reached a $74 million settlement with investors who accused the company of concealing a potential $10.7 billion U.S. tax bill, which they claimed artificially inflated Amgen's share price. The settlement, filed in federal court, does not include an admission of liability from …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

16:50 21 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?

Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings? Eli Lilly has followed the market's trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 per share while the index has …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%